Americas Irritable Bowel Syndrome (IBS) Treatment Market Research Report Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Forecast Till 2032

1 Report Prologue

2 Market Introduction

2.1 Scope of Study 11

2.2 Research Objective 11

2.3 Assumptions & Limitations 11

2.3.1 Assumptions 11

2.3.2 Limitations 11

2.4 Market Structure 12

3 Research Methodology

3.1.1 Primary Research Methodology 14

3.1.2 Data points received from the doctors/ gastrologist: 14

3.1.3 Data points received from the manufacturer/ pharmaceutical companies: 15

3.1.4 Data points received from Hospitals, Clinics: 15

3.1.5 Secondary Research Methodology 17

3.1.6 Market Share Analysis 19

3.1.7 Trade Analysis 19

3.1.8 Market Pricing Approach 19

4 Market Dynamics

4.1 Introduction 20

4.2 Drivers 21

4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%) 21

4.2.2 Strong clinical pipeline (Impact Weightage: 35%) 22

4.2.3 Increasing prevalence of depression (Impact Weightage: 28%) 23

4.3 Restraints 24

4.3.1 Strict FDA regulations (Impact Weightage: 60%) 24

4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%) 25

4.4 Opportunity 26

4.5 Mega Trends 27

4.6 Macroeconomic Indicators 28

5 Market Factor Analysis

5.1 Value Chain Analysis 29

5.1.1 Research and Development 29

5.1.2 Manufacturing 30

5.1.3 Distribution & Sales 30

5.1.4 Post-sales Monitoring 30

5.2 Porters Five Forces 31

5.2.1 Threat of New Entrants (Medium to High) 32

5.2.2 Bargaining power of suppliers (Medium) 32

5.2.3 Threat of Substitutes (Medium to High) 32

5.2.4 Bargaining Power of Buyers (Medium) 32

5.2.5 Intensity of Rivalry (Medium to High) 32

5.3 Demand & Supply: Gap Analysis 33

5.4 Pricing Analysis 33

5.5 Investment Opportunity Analysis 33

5.6 Merger and Acquisition Landscape 34

6 Americas IBS Treatment Market, By Type

6.1 Introduction 35

6.2 IBS-D 36

6.3 IBS-C 37

6.4 IBS-M 37

7 Americas IBS Treatment Market, By Drug Type

7.1 Introduction 38

7.2 Lubiprostone 39

7.3 Linaclotide 40

7.4 Eluxadoline 40

7.5 Rifaximin 40

7.6 Alosetron 41

8 Americas IBS Treatment Market, By End User

8.1 Introduction 42

8.2 Hospitals 43

8.3 Clinics 44

8.4 Research laboratories 44

9 Americas IBS treatment By Region

9.1 Introduction 45

9.1.1 North America 47

9.1.1.1 U.S. 48

9.1.1.2 Canada 50

9.1.2 South America 51

10 Company Landscape

11 Company Profiles

11.1 Allergan Plc 54

11.1.1 Company Overview 54

11.1.2 Financials 54

11.1.3 Products 54

11.1.4 Strategy 54

11.1.5 Key Developments 54

11.2 Sucampo Pharmaceuticals 55

11.2.1 Company Overview 55

11.2.2 Financials 55

11.2.3 Products 55

11.2.4 Strategy 55

11.2.5 Key Developments 55

11.3 Ironwood Pharmaceuticals, Inc. 56

11.3.1 Company Overview 56

11.3.2 Financials 56

11.3.3 Products 56

11.3.4 Strategy 56

11.3.5 Key Developments 56

11.4 Astellas Pharma Inc. 57

11.4.1 Company Overview 57

11.4.2 Financials 57

11.4.3 Products 57

11.4.4 Strategy 57

11.4.5 Key Developments 57

11.5 Valeant Pharmaceuticals 58

11.5.1 Company Overview 58

11.5.2 Financials 58

11.5.3 Products 58

11.5.4 Strategy 58

11.5.5 Key Developments 58

11.6 Abbott Laboratories 59

11.6.1 Company Overview 59

11.6.2 Financials 59

11.6.3 Products 59

11.6.4 Strategy 59

11.6.5 Key Developments 59

11.7 Synergy Pharmaceuticals, Inc. 60

11.7.1 Company Overview 60

11.7.2 Financials 60

11.7.3 Products 60

11.7.4 Strategy 60

11.7.5 Key Developments 60

11.8 Ardelyx, Inc. 61

11.8.1 Company Overview 61

11.8.2 Financials 61

11.8.3 Products 61

11.8.4 Strategy 61

11.8.5 Key Developments 61

11.9 Nestle 62

11.9.1 Company Overview 62

11.9.2 Financials 62

11.9.3 Products 62

11.9.4 Strategy 62

11.9.5 Key Developments 62

11.10 Sebela Pharmaceuticals 63

11.10.1 Company Overview 63

11.10.2 Financials 63

11.10.3 Products 63

11.10.4 Strategy 63

11.10.5 Key Developments 63

11.11 Probi 64

11.11.1 Company Overview 64

11.11.2 Financials 64

11.11.3 Products 64

11.11.4 Strategy 64

11.11.5 Key Developments 64

11.12 Alfasigma USA, Inc. 65

11.12.1 Company Overview 65

11.12.2 Financials 65

11.12.3 Products 65

11.12.4 Strategy 65

11.12.5 Key Developments 65

12 Conclusion

12.1 Key Findings 66

12.1.1 From CEO’s View Point 66

12.1.2 Unmet Needs 66

12.2 Key Companies to Watch 66

13 Appendix

13.1 Discussion Blue Print 67

14 List of tables

TABLE 1 PRIMARY INTERVIEWS 16

TABLE 2 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 35

TABLE 3 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36

TABLE 4 AMERICAS IBS TREATMENT MARKET FOR IBS-D SEGMENT, BY REGION, 2020-2027 (USD MILLION) 36

TABLE 5 AMERICAS IBS TREATMENT MARKET FOR IBS-C SEGMENT, BY REGION, 2020-2027 (USD MILLION) 37

TABLE 6 AMERICAS IBS TREATMENT MARKET FOR IBS-M SEGMENT, BY REGION, 2020-2027 (USD MILLION) 37

TABLE 7 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 38

TABLE 8 AMERICAS IBS TREATMENT MARKET FOR LUBIPROSTONE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 39

TABLE 9 AMERICAS IBS TREATMENT MARKET FOR LINACLOTIDE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 10 AMERICAS IBS TREATMENT MARKET FOR ELUXADOLINE SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 11 AMERICAS IBS TREATMENT MARKET FOR RIFAXIMIN SEGMENT, BY REGION, 2020-2027 (USD MILLION) 40

TABLE 12 AMERICAS IBS TREATMENT MARKET FOR ALOSETRON SEGMENT, BY REGION, 2020-2027 (USD MILLION) 41

TABLE 13 AMERICAS IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 42

TABLE 14 AMERICAS IBS TREATMENT MARKET FOR HOSPITALS SEGMENT, BY REGION, 2020-2027 (USD MILLION) 43

TABLE 15 AMERICAS IBS TREATMENT MARKET FOR CLINICS SEGMENT, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 16 AMERICAS IBS TREATMENT MARKET FOR RESEARCH LABORATORIES SEGMENT, BY REGION, 2020-2027 (USD MILLION) 44

TABLE 17 AMERICAS IBS TREATMENT MARKET, BY REGION 2020-2027 (USD MILLION) 46

TABLE 18 NORTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 47

TABLE 19 NORTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 47

TABLE 20 NORTH AMERICA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 48

TABLE 21 U.S. IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 48

TABLE 22 U.S. IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 49

TABLE 23 U.S. IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 49

TABLE 24 CANADA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 50

TABLE 25 CANADA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 50

TABLE 26 CANADA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 51

TABLE 27 SOUTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2020-2027 (USD MILLION) 51

TABLE 28 SOUTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2020-2027 (USD MILLION) 52

TABLE 29 SOUTH AMERICA IBS TREATMENT MARKET, BY END USER, 2020-2027 (USD MILLION) 52

15 List of Figures

FIGURE 1 AMERICAS IBS TREATMENT MARKET SHARE, BY TYPE, 2020 (%) 10

FIGURE 2 AMERICAS IBS TREATMENT MARKET SHARE, BY DRUG TYPE, 2020 (%) 10

FIGURE 3 RESEARCH METHODOLOGY 13

FIGURE 4 DATA TRIANGULATION PRIMARY 16

FIGURE 5 DATA TRIANGULATION METHOD 18

FIGURE 6 VALUE CHAIN: IRRITABLE BOWEL SYNDROME 29

FIGURE 7 PORTERS FIVE FORCES MODEL 31

FIGURE 8 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2020 & 2027 (USD MILLION) 39

FIGURE 9 AMERICAS IBS TREATMENT MARKET, BY END USER, 2020 & 2027 (USD MILLION) 43

FIGURE 10 AMERICAS IBS TREATMENT MARKET, BY REGION MARKET SHARE, 2020 (%) 46

FIGURE 11 AMERICAS IBS TREATMENT COMPANY MARKET SHARE, 2020 (%) 53